While it came as a disappointment, the failure of Biohaven Pharmaceutical Holding Company Ltd.’s verdiperstat in amyotrophic lateral sclerosis (ALS) was not a big surprise, and it won't impact the planned sale of Biohaven to Pfizer Inc. since the deal was tied to the migraine drug portfolio.
Biohaven's non-migraine pipeline is poised to be spun out into a new company, and the developments on that front have...